PURPOSE: Vitronectin (VN) in provisional extracellular matrix (ECM) promotes cell migration. Fibrotic ECM also includes VN and, paradoxically, strongly adherent myofibroblasts (Mfs). Because fibrotic Mfs secrete elevated amounts of urokinase plasminogen activator (uPA), we tested whether increased extracellular uPA promotes the persistence of Mfs on VN. METHODS: Primary human corneal fibroblasts (HCFs) were cultured in supplemented serum-free medium on VN or collagen (CL) with 1 ng/mL transforming growth factor β1 (TGFβ1). Adherent cells were quantified using crystal violet. Protein expression was measured by Western blotting and flow cytometry. Transfection of short interfering RNAs was performed by nucleofection. Mfs were identified by α-smooth muscle actin (α-SMA) stress fibers. Plasminogen activator inhibitor (PAI-1) levels were quantified by ELISA. RESULTS: TGFβ1-treated HCFs secreted PAI-1 (0.5 uM) that bound to VN, competing with αvβ3/αvβ5 integrin/VN binding, thus promoting cell detachment from VN. However, addition of uPA to cells on VN increased Mf differentiation (9.7-fold), cell-adhesion (2.2-fold), and binding by the VN integrins αvβ3 and -β5 (2.2-fold). Plasmin activity was not involved in promoting these changes, as treatment with the plasmin inhibitor aprotinin had no effect. A dominant negative PAI-1 mutant (PAI-1R) that binds to VN but does not inhibit uPA prevented the increase in uPA-stimulated cell adhesion and reduced uPA-stimulated integrin αvβ3/αvβ5 binding to VN by 73%. CONCLUSIONS: uPA induction of TGFβ1-dependent Mf differentiation on VN supports the hypothesis that elevated secretion of uPA in fibrotic tissue may promote cell adhesion and the persistence of Mfs. By blocking uPA-stimulated cell adhesion, PAI-1R may be a useful agent in combating corneal scarring.
PURPOSE:Vitronectin (VN) in provisional extracellular matrix (ECM) promotes cell migration. Fibrotic ECM also includes VN and, paradoxically, strongly adherent myofibroblasts (Mfs). Because fibrotic Mfs secrete elevated amounts of urokinase plasminogen activator (uPA), we tested whether increased extracellular uPA promotes the persistence of Mfs on VN. METHODS: Primary human corneal fibroblasts (HCFs) were cultured in supplemented serum-free medium on VN or collagen (CL) with 1 ng/mL transforming growth factor β1 (TGFβ1). Adherent cells were quantified using crystal violet. Protein expression was measured by Western blotting and flow cytometry. Transfection of short interfering RNAs was performed by nucleofection. Mfs were identified by α-smooth muscle actin (α-SMA) stress fibers. Plasminogen activator inhibitor (PAI-1) levels were quantified by ELISA. RESULTS: TGFβ1-treated HCFs secreted PAI-1 (0.5 uM) that bound to VN, competing with αvβ3/αvβ5 integrin/VN binding, thus promoting cell detachment from VN. However, addition of uPA to cells on VN increased Mf differentiation (9.7-fold), cell-adhesion (2.2-fold), and binding by the VN integrins αvβ3 and -β5 (2.2-fold). Plasmin activity was not involved in promoting these changes, as treatment with the plasmin inhibitor aprotinin had no effect. A dominant negative PAI-1 mutant (PAI-1R) that binds to VN but does not inhibit uPA prevented the increase in uPA-stimulated cell adhesion and reduced uPA-stimulated integrin αvβ3/αvβ5 binding to VN by 73%. CONCLUSIONS:uPA induction of TGFβ1-dependent Mf differentiation on VN supports the hypothesis that elevated secretion of uPA in fibrotic tissue may promote cell adhesion and the persistence of Mfs. By blocking uPA-stimulated cell adhesion, PAI-1R may be a useful agent in combating corneal scarring.
Authors: L Postiglione; N Montuori; A Riccio; G Di Spigna; S Salzano; G Rossi; P Ragno Journal: Int J Immunopathol Pharmacol Date: 2010 Jul-Sep Impact factor: 3.219
Authors: Jacqueline M Cale; Shih-Hon Li; Mark Warnock; Enming J Su; Paul R North; Karen L Sanders; Maria M Puscau; Cory D Emal; Daniel A Lawrence Journal: J Biol Chem Date: 2010-01-08 Impact factor: 5.157
Authors: Thomas J Podor; Davindra Singh; Paul Chindemi; Denise M Foulon; Robert McKelvie; Jeffrey I Weitz; Richard Austin; Ghislain Boudreau; Richard Davies Journal: J Biol Chem Date: 2001-12-14 Impact factor: 5.157
Authors: Yufeng Huang; Wayne A Border; Ling Yu; Jiandong Zhang; Daniel A Lawrence; Nancy A Noble Journal: J Am Soc Nephrol Date: 2008-01-23 Impact factor: 10.121
Authors: J Steven Jacobsen; Thomas A Comery; Robert L Martone; Hassan Elokdah; David L Crandall; Aram Oganesian; Suzan Aschmies; Yolanda Kirksey; Cathleen Gonzales; Jane Xu; Hua Zhou; Kevin Atchison; Erik Wagner; Margaret M Zaleska; Indranil Das; Robert L Arias; Jonathan Bard; David Riddell; Stephen J Gardell; Magid Abou-Gharbia; Albert Robichaud; Ronald Magolda; George P Vlasuk; Thorir Bjornsson; Peter H Reinhart; Menelas N Pangalos Journal: Proc Natl Acad Sci U S A Date: 2008-06-16 Impact factor: 11.205
Authors: Lingyan Wang; Chun-Ying Ko; Erin E Meyers; Benjamin S Pedroja; Nadia Pelaez; Audrey M Bernstein Journal: Mol Vis Date: 2011-11-02 Impact factor: 2.367
Authors: Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma Journal: Lab Invest Date: 2014-03-31 Impact factor: 5.662
Authors: E El Khouri; J Ghoumid; D Haye; F Giuliano; L Drevillon; A Briand-Suleau; P De La Grange; V Nau; T Gaillon; T Bienvenu; H Jacquemin-Sablon; M Goossens; S Amselem; I Giurgea Journal: Mol Psychiatry Date: 2021-04-19 Impact factor: 15.992